48 results on '"Werneburg, Brian"'
Search Results
2. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder
3. Assessing the extent of symptom control provided by ravulizumab or efgartigimod in generalised myasthenia gravis
4. Change in concomitant therapies for generalized myasthenia gravis in patients receiving eculizumab: A retrospective analysis of registry data
5. Clinical and real-world pharmacovigilance data of meningococcal infections in eculizumab- or ravulizumab-treated patients
6. Identifying digital biomarkers for the self-monitoring of patients living with generalized myasthenia gravis: A proof of concept
7. Identifying Digital Biomarkers for the Self-Monitoring of Patients Living with Generalized Myasthenia gravis: a Proof of Concept (P7-8.007)
8. Change in Concomitant Therapies for Generalized Myasthenia Gravis in Patients Receiving Eculizumab: a Retrospective Analysis of Registry Data (P1-5.002)
9. Impact of Treating Depression on Associated Comorbidities
10. Impact of Major Depressive Disorder on Comorbidities
11. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder
12. Characterizing Treatment Utilization Patterns for Trigeminal Neuralgia in the United States
13. Characterization of Hypoactive Sexual Desire Disorder (HSDD) in Men
14. Molecular Basis of MAPK-Activated Protein Kinase 2:p38 Assembly
15. Effect of Zuranolone vs Placebo in Postpartum Depression
16. Rapid and Sustained Improvement in Concurrent Symptoms of Depression and Anxiety in a Post Hoc Analysis of Zuranolone Treatment in Postpartum Depression
17. Zuranolone in Major Depressive Disorder: Interim Efficacy Results From a Phase 3, Open-Label, Longitudinal Study
18. Zuranolone in Major Depressive Disorder: Interim Safety Results From a Phase 3, Open-Label, Longitudinal Study
19. Evaluation of Insomnia Symptoms in a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial of Zuranolone in Postpartum Depression
20. Discovery and characterization of a substrate selective p38alpha inhibitor
21. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Patients With Major Depressive Disorder
22. SAGE-217 in Postpartum Depression (PPD): Number Needed to Treat (NNT) From a Phase 3, Randomized, Placebo-Controlled Trial
23. Effect of SAGE-217 on Anxiety Outcomes in Postpartum Depression in a Randomized, Placebo-Controlled Trial
24. SAGE-217 in Major Depressive Disorder: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial (705)
25. Supplemental material for Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results
26. Pim Kinase Substrate Identification and Specificity
27. Experimental Autoimmune Encephalomyelitis Induction in Peptidylarginine Deiminase 2 Knockout Mice
28. Vosuper2+(IV) complexes with pyruvate carboxylase: Activation of oxaloacetate decarboxylation and EPR properties of enzyme-Vosuper2+ complexes
29. DNA polymerase beta: multiple conformational changes in the mechanism of catalysis
30. DNA polymerase beta: structure-fidelity relationship from pre-steady-state kinetic analyses of all possible correct and incorrect base pairs for wild type and R283A mutant
31. DNA polymerase beta: pre-steady state kinetic analysis and roles of arginine-283 in catalysis and fidelity
32. T111. Patient-Reported Health-Related Quality of Life Correlates Inversely With Depressive Symptoms in a Pivotal Trial of SAGE-217 in Major Depressive Disorder
33. Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results
34. Subcutaneous Peginterferon β-1a injection-site Reaction Experience and Mitigation: Delphi Analysis of the Allow Study
35. Catalysis and function of the p38alpha.Mk2a signaling complex
36. COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
37. Synthesis and SAR studies of indole-based MK2 inhibitors
38. Sexual Concerns Inventory-Male
39. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors
40. Molecular Characterization of CD40 Signaling Intermediates
41. DNA polymerase β: effects of gapped DNA substrates on dNTP specificity, fidelity, processivity and conformational changes
42. VO2+(IV) Complexes with Pyruvate Carboxylase: Activation of Oxaloacetate Decarboxylation and EPR Properties of Enzyme−VO2+ Complexes
43. DNA Polymerase β: Multiple Conformational Changes in the Mechanism of Catalysis
44. DNA polymerase β: analysis of the contributions of tyrosine-271 and asparagine-279 to substrate specificity and fidelity of DNA replication by pre-steady-state kinetics
45. DNA Polymerase β: Structure−Fidelity Relationship from Pre-Steady-State Kinetic Analyses of All Possible Correct and Incorrect Base Pairs for Wild Type and R283A Mutant
46. DNA Polymerase β: Pre-Steady-State Kinetic Analysis and Roles of Arginine-283 in Catalysis and Fidelity
47. Catalysis and Function of the p38α-MK2a Signaling Complex.
48. Catalysis and function of the p38 alpha.MK2a signaling complex.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.